Rituximab/Bendamustine treatment of chronic lymphatic leukemia leads to sustained remission of antiphospholipid antibodies

Eur J Immunol. 2019 Jun;49(6):969-970. doi: 10.1002/eji.201848042. Epub 2019 May 14.

Authors

Paul Rj Ames¹, Mira Merashli², Fabrizio Gentile^{3

4}

Affiliations

¹ Immune Response and Vascular Disease Unit, Nova University, Lisbon, Portugal.
² Department of Haematology, Dumfries Royal Infirmary, Scotland, UK.
³ Department of Rheumatology, American University of Beirut, Beirut, Lebanon.
⁴ Department of Medicine and Health Sciences, Universita' del Molise, Campobasso, Italy.

PMID: 30893471
DOI: 10.1002/eji.201848042

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Antiphospholipid Syndrome / complications*
Bendamustine Hydrochloride / administration & dosage
Female
Humans
Leukemia, Lymphocytic, Chronic, B-Cell / complications*
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
Middle Aged
Rituximab / administration & dosage

Substances

Rituximab
Bendamustine Hydrochloride